Skip to main content
Caplight Logo









Immunomic Therapeutics

Immunomic Therapeutics

Private
Rockville, MarylandHealthcare & Life Scienceshttps://immunomix.com/

Last Round

VC Round

Jan 14, 2021

Total Funding Raised

$15.53M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Immunomic Therapeutics is a biotechnology company that develops nucleic acid-based vaccines and immunotherapies for oncology, infectious diseases, and allergies using its proprietary UNITE platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

nucleic acid vaccineimmunotherapybiotechnologylysosomal targetingDNA vaccineoncologyantigen presentationclinical-stage biotechdrug discoverymRNA vaccineT-cell activationbiotech licensingvaccine platformcold tumor therapynext-gen vaccines

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immunomic Therapeutics Comparables

Compare Immunomic Therapeutics with similar companies based on industry and business-model similarity.

Immunomic Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MimiVax Inc.
81%
Takis S.r.l.
78%
Elicio Therapeutics
77%

Immunomic Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 14, 2021
DebtMar 15, 2017
Series AOct 28, 2014
DebtJul 17, 2013
AngelMar 5, 2012

Key People

Founding team and executive leadership

Dong-Gun Kim

Chief Executive Officer

Executive Team

Immunomic Therapeutics Investors

Notable investors and investment history

Immunomic Therapeutics investors
InvestorRounds
Life Sciences Greenhouse InvestmentsDebt
Keiretsu ForumDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 6, 3x the trailing average.

  • Jan 14, 2021

    $78M round led by HLB Co., Ltd.

Immunomic Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Immunomic Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Immunomic Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range20
Year Founded2006
Last FundingJan 14, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?